3-(6-methoxy-pyridin-3-yl)-3-oxo-propionitrile | 932040-51-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(6-methoxy-pyridin-3-yl)-3-oxo-propionitrile
• 英文别名: 3-(6-methoxypyridin-3-yl)-3-oxopropanenitrile
• CAS: 932040-51-2
• 化学式: C₉H₈N₂O₂
• 分子量: 176.175
• InChiKey: CMCWMVGVASVCNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,4-二硫-2,5-二醇 、 3-(6-methoxy-pyridin-3-yl)-3-oxo-propionitrile 在 diethyl ether petroleum ether 作用下， 以 吗啉 、 乙醇 为溶剂， 反应 0.17h， 以providing the title compound as a yellow solid (948 mg, 71% yield)的产率得到(2-amino-thiophen-3-yl)-(6-methoxy-pyridin-3-yl)-methanone
  参考文献：
  名称：

  THIOPHENE DERIVATIVES AS PPAR AGONISTS I

  摘要：

  本发明揭示了式(I)的化合物;其中：R是羧酸或其衍生物; R1是烷基，烯基，炔基，环烷基，烷氧基，烷硫基，卤素或三卤甲基; R2是芳基，杂环芳基，芳基烷基或杂环芳基烷基; R3是H或F; L是一个链接基团，包括从2到8个原子的链连接R和羰基(A);以及其药学上可接受的衍生物，用于治疗通过过氧化物酶体增殖物激活受体(PPAR)亚型δ (PPARδ)介导的疾病。因此，本发明的化合物在代谢综合征、肥胖症、2型糖尿病、脂质代谢异常、伤口愈合、炎症、神经退行性疾病和多发性硬化症的治疗中有用。

  公开号：

  US20100063065A1

文献信息

• [EN] ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS<br/>[FR] INHIBITEURS DE RÉCEPTEURS NICOTINIQUES ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：WYETH CORP

  公开号：WO2010009290A1

  公开（公告）日：2010-01-21

  The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.

  本发明提供了化合物和组合物，制备它们的方法，以及利用它们调节α7烟碱乙酰胆碱受体和/或治疗各种疾病、疾病和症状的方法。所提供的化合物可以影响神经系统、精神病学和/或炎症系统等方面。
• ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS
  申请人：Bothmann Hendrick

  公开号：US20100130474A1

  公开（公告）日：2010-05-27

  The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.

  本发明提供了化合物和组合物，制备它们的方法以及使用它们调节α7尼古丁乙酰胆碱受体和/或治疗各种疾病、疾病和情况的方法。所提供的化合物可以影响神经系统、精神病和/或炎症系统等方面。
• Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation
  作者：William T. McElroy、Zheng Tan、Ginny Ho、Sunil Paliwal、Guoqing Li、W. Michael Seganish、Deen Tulshian、James Tata、Thierry O. Fischmann、Christopher Sondey、Hong Bian、Loretta Bober、James Jackson、Charles G. Garlisi、Kristine Devito、James Fossetta、Daniel Lundell、Xiaoda Niu

  DOI：10.1021/acsmedchemlett.5b00106

  日期：2015.6.11

  IRAK4 is a critical upstream kinase in the IL-1R/TLR signaling pathway. Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders. A screening campaign identified a pyrazole class of IRAK4 inhibitors that were determined by X-ray crystallography to exhibit an unusual binding mode. SAR efforts focused on the identification of a potent and selective inhibitor with good aqueous solubility and rodent pharmacokinetics. Pyrazole C-3 piperidines were well tolerated, with N-sulfonyl analogues generally having good rodent oral exposure but poor solubility. N-Alkyl piperidines exhibited excellent solubility and reduced exposure. Pyrazoles possessing NI pyridine and fluorophenyl substituents were among the most active. Piperazine 32 was a potent enzyme inhibitor with good cellular activity. Compound 32 reduced the in vivo production of proinflammatory cytokines and was orally efficacious in a mouse antibody induced arthritis disease model of inflammation.
• WO2007/36730
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] THIOPHENE DERIVATIVES AS PPAR AGONISTS I<br/>[FR] DERIVES DE THIOPHENE UTILISES COMME AGONISTES I DU RECEPTEUR PPAR
  申请人：INPHARMATICA LTD

  公开号：WO2007036730A1

  公开（公告）日：2007-04-05

  [EN] The invention discloses compounds of formula (I); wherein: R is a carboxylic acid or a derivative thereof; R¹ is alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylthio, halo or trihalomethyl; R² is aryl, heteroaryl, arylalkyl or heteroarylalkyl; R³ is H or F; and L is a linking group comprising a chain of from 2 to 8 atoms linking R and the carbonyl group (A); and pharmaceutically acceptable derivatives thereof, useful for treating disorders mediated by peroxisome-proliferator-activated receptor (PPAR) subtype d (PPARd). The compounds of the invention are therefore useful in the treatment of metabolic syndrome, obesity, type-II diabetes, dyslipidemia, wound healing, inflammation, neurodegenerative disorders and multiple sclerosis.
  [FR] La présente invention concerne des composés représentés par la formule (I) dans laquelle R désigne un acide carboxylique ou un dérivé de celui-ci, R¹ désigne alkyle, alcényle, alkynyle, cycloalkyle, alcoxy, alkylthio, halo ou trihalométhyle; R² désigne aryle, hétéroaryle, arylalkyle ou hétéroarylalkyle; R³ désigne H ou F; et L désigne un groupe de liaison comprenant une chaîne de 2 à 8 atomes liant R et le groupe carbonyle (A), et des dérivés pharmaceutiquement acceptables de ces composés, lesquels peuvent être utilisés pour traiter des troubles induits par le récepteur activé par les proliférateurs des peroxisomes (PPAR) de sous-type d (PPARd). Les composés de cette invention peuvent ainsi être utilisés pour traiter le syndrome métabolique, l'obésité, le diabète de type II, la dyslipidémie, la cicatrisation des plaies, l'inflammation, les troubles neurodégénératifs et la sclérose en plaques.